Abstract
The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%. We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes. A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P < .0001), grade 3/4 irAEs (P = .0025), leading to discontinuation irAEs (P = .0144), multiple-site and single-site irAEs (P < .0001), cutaneous irAEs (P = .0001), endocrine irAEs (P = .0227), pulmonary irAEs (P = .0479), and rheumatologic irAEs (P = .0018) were significantly related to a higher objective response rate. Any grade irAEs (P < .0001), single-site irAEs (P < .0001), multiple-site irAEs (P = .0005), cutaneous irAEs (P = .0042), endocrine...Continue Reading
References
Sep 1, 1993·Immunology Today·N R Rose, C Bona
Apr 12, 2015·Clinical Lung Cancer·Cesare GridelliFilippo de Marinis
Dec 31, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S ChampiatA Marabelle
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Aug 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfMichael A Postow
Sep 25, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shunsuke TeraokaKeisuke Tomii
Oct 5, 2017·JAMA Oncology·Koji HarataniKazuhiko Nakagawa
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Apr 7, 2018·Therapeutic Advances in Medical Oncology·Aaron SosaRafael Rosell
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Oct 20, 2018·Clinical Lung Cancer·Doran KsienskiMary Lesperance
Dec 7, 2018·Journal of Cancer Research and Clinical Oncology·Biagio RicciutiRita Chiari
Jan 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckJulie R Brahmer
Feb 24, 2019·The Oncologist·Alessio CortelliniCorrado Ficorella
Mar 20, 2019·Clinical Lung Cancer·Alessio CortelliniSebastiano Buti
Apr 26, 2019·JAMA Oncology·Yucai WangMichael L Wang
Apr 26, 2019·JAMA Oncology·Fiamma BernerLukas Flatz
May 1, 2019·The Oncologist·Narjust DumaRoxana S Dronca
May 7, 2019·Frontiers in Oncology·Alfredo AddeoMassimo Di Maio
Aug 26, 2019·Clinical Lung Cancer·Jun FukiharaYoshinori Hasegawa
Nov 2, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Filippo G Dall'OlioFrancesco Massari
Nov 16, 2019·Seminars in Oncology·Alessio CortelliniMelissa Bersanelli
Nov 16, 2019·Journal of Translational Medicine·Alessio CortelliniPaolo A Ascierto
Nov 27, 2019·Current Oncology Reports·Alex FriedlaenderAlfredo Addeo
Jan 3, 2020·JAMA Oncology·Alexander M M EggermontStefan Suciu
Feb 29, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alessio CortelliniPaolo A Ascierto
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee
Mar 23, 2020·Clinical Lung Cancer·Yuichi TamboKazuo Kasahara
May 27, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Olga NigroAlessio Cortellini
Jun 1, 2020·Cancer Immunology, Immunotherapy : CII·Alessio CortelliniGiampiero Porzio
Citations
Aug 9, 2020·Rheumatology International·Guilherme Ferreira Maciel da SilvaFrancisco Airton Castro Rocha
Oct 21, 2020·Journal for Immunotherapy of Cancer·Alessio CortelliniCorrado Ficorella
Feb 3, 2021·Thoracic Cancer·Alessio CortelliniGiampiero Porzio
Feb 14, 2021·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·David Tak Wai LuiThomas Yau
Jan 9, 2021·Journal of Neuro-oncology·Michael ZhangGordon Li
Mar 9, 2021·World Journal of Clinical Oncology·Monica PeravaliIrina Veytsman
Mar 13, 2021·Thoracic Cancer·Taisuke IsonoNoboru Takayanagi
Mar 19, 2021·Frontiers in Oncology·Donghui WangFang Zhang
Mar 19, 2021·ESMO Open·G L BannaA Addeo
Apr 4, 2021·Journal of Clinical Medicine·Edoardo LenciRossana Berardi
Apr 9, 2021·Journal for Immunotherapy of Cancer·Alessio CortelliniDavid J Pinato
May 3, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sebastiano ButiAlessio Cortellini
May 6, 2021·Thoracic Cancer·Yi-Hui LiLi Zhang
Jul 6, 2021·Frontiers in Oncology·Angela DamatoCarmine Pinto
Jul 6, 2021·Frontiers in Oncology·Lotte Van Der WeijstYolande Lievens
Jun 30, 2021·Clinical Lung Cancer·Yanlin LiHui Guo
Jul 2, 2021·Cancer Immunology, Immunotherapy : CII·E Suazo-ZepedaG Sidorenkov
Aug 10, 2021·Frontiers in Medicine·Yuko KuboMasahiko Kusumoto
Aug 20, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Vito TotaStéphane Holbrechts
Sep 1, 2021·Cancer Immunology, Immunotherapy : CII·Marco RussanoDaniele Santini
Oct 5, 2021·Frontiers in Oncology·Zhe ZhaoXiaoguang Chen